A
EGRX

AJOVista’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

AJOVista’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$211K Buy
56,438
+45,206
+402% +$216K 0.9% 31
2024
Q2 		$62.9K Hold
11,232
– – 0.18% 64
2024
Q1 		$58.9K Buy
+11,232
New +$61.6K 0.16% 77

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AJOVista's EGRX Position: Q3 2024 in Review

AJOVista increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 402% in Q3 2024, buying an estimated $216K and bringing the position to 56,438 shares worth $211K. The position accounts for 0.9% of the portfolio, ranked #31.

AJOVista first reported a position in EGRX in Q1 2024 and has held it in 3 quarters since. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • AJOVista held 56,438 shares of Eagle Pharmaceuticals, Inc. worth $211K as of Q3 2024.
  • AJOVista bought 45,206 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $216K.
  • Eagle Pharmaceuticals, Inc. made up 0.9% of AJOVista's portfolio in Q3 2024, its #31 holding.
  • AJOVista first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2024 and has held it in 3 quarters since.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on AJOVista's 13F filing for Q3 2024, filed 12 Nov 2024.